These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7124508)

  • 1. Possible interaction between cholecystokinin and dopamine.
    Govoni S; Yang HY; Bosio A; Pasinetti G; Costa E
    Adv Biochem Psychopharmacol; 1982; 33():437-44. PubMed ID: 7124508
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine- and cholecystokinin-containing neurons of the crossed mesostriatal projection.
    Fallon JH; Wang C; Kim Y; Canepa N; Loughlin S; Seroogy K
    Neurosci Lett; 1983 Oct; 40(3):233-8. PubMed ID: 6316210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intracerebroventricular administration of cholecystokinin inhibits the dopamine- and serotoninergic systems of the brain].
    Vasar EE; Otter MIa; Riago LK
    Fiziol Zh SSSR Im I M Sechenova; 1982 Sep; 68(9):1218-22. PubMed ID: 7173435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat.
    Mufson EJ; Kroin JS; Sobreviela T; Burke MA; Kordower JH; Penn RD; Miller JA
    Exp Neurol; 1994 Sep; 129(1):15-26. PubMed ID: 7523178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
    Zeevalk GD; Manzino L; Sonsalla PK
    Exp Neurol; 2000 Feb; 161(2):638-46. PubMed ID: 10686083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroscience. A timely debate about the brain.
    Bhattacharjee Y
    Science; 2006 Feb; 311(5761):596-8. PubMed ID: 16456050
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.
    Natsume A; Mata M; Goss J; Huang S; Wolfe D; Oligino T; Glorioso J; Fink DJ
    Exp Neurol; 2001 Jun; 169(2):231-8. PubMed ID: 11358438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of dopaminergic systems of the neostriatum in processes of higher nervous activity in animals and man].
    Suvorov NF; Volynkina GIu
    Fiziol Zh SSSR Im I M Sechenova; 1986 Jan; 72(1):48-55. PubMed ID: 2868929
    [No Abstract]   [Full Text] [Related]  

  • 12. Glial responses associated with dopaminergic striatal reinnervation following lesions of the rat substantia nigra.
    Stanic D; Tripanichkul W; Drago J; Finkelstein DI; Horne MK
    Brain Res; 2004 Oct; 1023(1):83-91. PubMed ID: 15364022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa.
    Ogawa N; Edamatsu R; Mizukawa K; Asanuma M; Kohno M; Mori A
    Adv Neurol; 1993; 60():242-50. PubMed ID: 8380518
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ; György L
    Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
    Bentlage C; Nikkhah G; Cunningham MG; Björklund A
    Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation of mesencephalic cell suspension in dopamine-denervated striatum of the rat.I. Effects on spontaneous activity of striatal neurons.
    Di Loreto S; Florio T; Capozzo A; Napolitano A; Adorno D; Scarnati E
    Exp Neurol; 1996 Apr; 138(2):318-26. PubMed ID: 8620930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct regional differences in dopamine-mediated volume transmission.
    Rice ME
    Prog Brain Res; 2000; 125():277-90. PubMed ID: 11098664
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuromodulatory actions of dopamine and cholecystokinin in the ventral striatum.
    Yim CC; Sheehy L; Mogenson G
    Adv Exp Med Biol; 1991; 295():169-82. PubMed ID: 1776567
    [No Abstract]   [Full Text] [Related]  

  • 20. Can graft-derived neurotrophic activity be used to direct axonal outgrowth of grafted dopamine neurons for circuit reconstruction in primates?
    Sladek JR; Collier TJ; Elsworth JD; Taylor JR; Roth RH; Redmond DE
    Exp Neurol; 1993 Nov; 124(1):134-9. PubMed ID: 8282070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.